Cargando…
Long-term efficacy and safety of subcutaneous C1-inhibitor in women with hereditary angioedema: subgroup analysis from an open-label extension of a phase 3 trial
BACKGROUND: Women with hereditary angioedema due to C1-inhibitor deficiency (HAE-C1INH) experience more frequent and severe angioedema attacks compared with men. Fluctuations in female sex hormones can influence HAE attack frequency and severity. Subcutaneous C1-INH (C1-INH [SC]) is indicated as rou...
Autores principales: | Levy, Donald S., Farkas, Henriette, Riedl, Marc A., Hsu, Florence Ida, Brooks, Joel P., Cicardi, Marco, Feuersenger, Henrike, Pragst, Ingo, Reshef, Avner |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7001333/ https://www.ncbi.nlm.nih.gov/pubmed/32042283 http://dx.doi.org/10.1186/s13223-020-0409-3 |
Ejemplares similares
-
Long-Term Efficacy of Subcutaneous C1 Inhibitor in Pediatric Patients with Hereditary Angioedema
por: Levy, Donald, et al.
Publicado: (2020) -
Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo-controlled randomized study
por: Li, H. Henry, et al.
Publicado: (2019) -
Patterns of on-demand medication use in patients with hereditary angioedema treated long-term with prophylactic subcutaneous C1-inhibitor
por: Levy, Donald S., et al.
Publicado: (2019) -
Biomarkers in Hereditary Angioedema
por: Porebski, Grzegorz, et al.
Publicado: (2021) -
Exposure‐Response Model of Subcutaneous C1‐Inhibitor Concentrate to Estimate the Risk of Attacks in Patients With Hereditary Angioedema
por: Zhang, Ying, et al.
Publicado: (2018)